PepsRadar
⌕ Search✧ Ask
These 13 profiles mention blood thinners or bleeding problems in their Risks & interactions section, from the FDA label for approved drugs or from published studies for research compounds. Open a profile and read that section to see exactly why.
A peptide that isn't listed may simply have no human safety data, which doesn't make it safe for you. Dashed tags on investigational GLP-1 drugs come from the labels of approved drugs in the same class. Not medical advice: talk to a doctor or pharmacist about your own situation. All peptides · Heart or blood pressure problems · Diabetes or blood-sugar medicines · Cancer, now or in the past · Pregnancy or breastfeeding · Kidney problems · Liver problems
Bivalirudin is a direct thrombin-inhibitor peptide used in procedural anticoagulation. The featured analysis examined patients with ST-elevation myocardial infarction undergoing coronary intervention.
Prescription medicines
Read the risks →Dulaglutide, marketed as Trulicity, is a long-acting GLP-1 receptor agonist used in type 2 diabetes care. Its research includes blood-sugar control and cardiovascular outcomes.
Prescription medicines
Read the risks →Efpeglenatide is an exendin-based GLP-1 receptor agonist. AMPLITUDE-O examined cardiovascular and kidney outcomes in a high-risk type 2 diabetes population.
Research topics
Read the risks →Enfuvirtide is an HIV fusion inhibitor with historical combination-treatment evidence. MedlinePlus reports that the injection has been discontinued in the United States.
Clinical medicines
Read the risks →Exenatide is an incretin medicine used in type 2 diabetes. Short-acting and extended-release products need to be distinguished when reading evidence.
Prescription medicines
Read the risks →Glucagon is a hormone medicine used to raise dangerously low blood glucose. It serves a different role from medicines aimed at lowering glucose or weight.
Prescription medicines
Read the risks →Mazdutide is a dual GLP-1 and glucagon receptor agonist studied for weight management. GLORY-1 tested it in Chinese adults with overweight or obesity.
Research topics
Read the risks →Pemvidutide is a dual GLP-1 and glucagon receptor agonist investigated in metabolic dysfunction-associated steatohepatitis (MASH). Its liver-biopsy outcomes should be separated from weight-loss claims.
Research topics
Read the risks →Retatrutide is a triple-receptor agonist investigated for obesity and related metabolic conditions. Its trial identity differs from unverified coded seller listings.
Investigational
Read the risks →Survodutide is a dual GLP-1 and glucagon receptor agonist. A 2026 phase 3 publication reports weight outcomes in adults with obesity or overweight without diabetes.
Research topics
Read the risks →Tirzepatide is a dual-incretin medicine with distinct product and indication contexts. Its clinical-trial material is not interchangeable with a research-use vial.
Prescription medicines
Read the risks →Arginine vasopressin is a nine-residue hormone involved in water balance and vascular tone. VASST compared vasopressin with norepinephrine in septic shock.
Prescription medicines
Read the risks →Ziconotide is a venom-derived peptide medicine that blocks N-type calcium channels. Its pain research concerns specialist intrathecal delivery, not a generic injectable recovery peptide.
Prescription medicines
Read the risks →See something wrong on this page? Report a mistake · Corrections
